drugset
drugset / Trial / NCT01239875

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01239875 ↗

Phase 0 Completed 16 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Giving vaccine therapy together with cryosurgery may kill more tumor cells. PURPOSE: This clinical trial studies giving vaccine therapy together with or without cryosurgery in treating patients with B-cell Non-Hodgkin's lymphoma.

Timeline

Start
2010-11
Primary completion
2015-11-24
Completion
2019-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Pneumovax 23 Vaccine — Intramuscular
Subject autologous dendritic cell-tumor fusion vaccine Vaccine — Other
Subject dendritic cell vaccine therapy Vaccine — Other

Indications

MALT lymphoma Waldenstrom macroglobulinemia chronic lymphocytic leukemia/small lymphocytic lymphoma grade III lymphomatoid granulomatosis large-cell immunoblastic lymphoma lymphoblastic lymphoma mantle cell lymphoma nodal marginal zone B-cell lymphoma primary cutaneous B-cell lymphoma splenic marginal zone lymphoma